High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification

Atherosclerosis. 2011 Dec;219(2):538-44. doi: 10.1016/j.atherosclerosis.2011.08.027. Epub 2011 Aug 22.

Abstract

Objective: To determine whether differences exist in valvular high density lipoprotein (HDL) content between non-stenotic and stenotic aortic valves, and whether HDL could retard valvular calcification locally.

Methods: Stenotic aortic valves were obtained from valve replacement surgery and non-stenotic control valves from cardiac transplantations or at autopsy. The valvular localization and concentration of apolipoproteinA-I (apoA-I) were analyzed by immunohistochemistry and ELISA. The effects of HDL on the secretion of calcifying mediators and proinflammatory cytokines by cultured aortic valve myofibroblasts were assessed by ELISA and real-time PCR.

Results: The concentration of apoA-I was higher in control than in stenotic valves (p < 0.05). ApoA-I surrounded the calcific deposits in stenotic valves, co-localizing with apoB, apoE, and osteoprotegerin (OPG). Incubation of cultured valve myofibroblasts with HDL increased their secretion of OPG (p < 0.001). Furthermore, incubation of myofibroblasts with HDL led to decreased mRNA expression of tumor necrosis factor alpha (TNF-α) (p < 0.05).

Conclusions: The amount of valvular HDL is reduced in aortic valve stenosis. HDL both induces the secretion of OPG and reduces the expression of TNF-α in vitro. Since OPG is known to inhibit and TNF-α to promote aortic valve calcification, HDL may have an anti-calcifying effect in human aortic valves.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aortic Valve / metabolism*
  • Aortic Valve / surgery
  • Aortic Valve Stenosis / genetics
  • Aortic Valve Stenosis / metabolism*
  • Aortic Valve Stenosis / surgery
  • Apolipoprotein A-I / genetics
  • Apolipoprotein A-I / metabolism
  • Apolipoproteins B / metabolism
  • Apolipoproteins E / metabolism
  • Autopsy
  • Calcinosis / genetics
  • Calcinosis / metabolism*
  • Calcinosis / prevention & control
  • Calcinosis / surgery
  • Case-Control Studies
  • Cells, Cultured
  • Down-Regulation
  • Enzyme-Linked Immunosorbent Assay
  • Finland
  • Heart Valve Prosthesis Implantation
  • Humans
  • Immunohistochemistry
  • Inflammation Mediators / metabolism
  • Lipoproteins, HDL / metabolism*
  • Myofibroblasts / metabolism
  • Osteoprotegerin / metabolism
  • RNA, Messenger / metabolism
  • Real-Time Polymerase Chain Reaction
  • Severity of Illness Index
  • Time Factors
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • APOA1 protein, human
  • Apolipoprotein A-I
  • Apolipoproteins B
  • Apolipoproteins E
  • Inflammation Mediators
  • Lipoproteins, HDL
  • Osteoprotegerin
  • RNA, Messenger
  • TNFRSF11B protein, human
  • Tumor Necrosis Factor-alpha